1 protective effects of korean red ginseng against alcohol-induced fatty liver in rats

2 Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled, double-blind clinical trial.

3 Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease.

4 A Mediterranean Diet Rich in Extra-Virgin Olive Oil Is Associated with a Reduced Prevalence of Nonalcoholic Fatty Liver Disease in Older Individuals at High Cardiovascular Risk.

5 Evaluation of diffusion kurtosis imaging in stratification of nonalcoholic fatty liver disease and early diagnosis of nonalcoholic steatohepatitis in a rabbit model.

6 Augmented intelligence with natural language processing applied to electronic health records for identifying patients with non-alcoholic fatty liver disease at risk for disease progression.

7 Association Between Nonalcoholic Fatty Liver Disease and Severe Male Reproductive Organ Impairment (Germinal Epithelial Loss): Study on a Mouse Model and on Human Patients

8 Reduction of some atherogenic indices in patients with non-alcoholic fatty liver by Vitamin D and calcium co-supplementation: A double blind randomized controlled clinical trial

9 [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].

10 Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease

11 Inhibition of lncRNA HULC improves hepatic fibrosis and hepatocyte apoptosis by inhibiting the MAPK signaling pathway in rats with nonalcoholic fatty liver disease

12 Erratum: Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease (Cell Metabolism (2017) 25(5) (1054–1062.e5), (S1550413117302061), (10.1016/j.cmet.2017.04.001))

13 Neutrophil-to-lymphocyte ratio is independently associated with inflammatory activity and fibrosis grade in nonalcoholic fatty liver disease

14 Validation Study of Elastographies in Patients With Nonalcoholic Fatty Liver Disease for Detecting Liver Fibrosis

15 The Role of Lipid and Lipoprotein Metabolism in Non‐Alcoholic Fatty Liver Disease

16 Estrogen-related receptor γ controls sterol regulatory element-binding protein-1c expression and alcoholic fatty liver.

17 Raw Bowl Tea (Tuocha) Polyphenol Prevention of Nonalcoholic Fatty Liver Disease by Regulating Intestinal Function in Mice.

18 TRIB1 rs17321515 gene polymorphism increases the risk of coronary heart disease in general population and non-alcoholic fatty liver disease patients in Chinese Han population.

19 Sleep Disruption and Daytime Sleepiness Correlating with Disease Severity and Insulin Resistance in Non-Alcoholic Fatty Liver Disease: A Comparison with Healthy Controls.

20 Hepatic Mitochondrial Defects in a Nonalcoholic Fatty Liver Disease Mouse Model Are Associated with Increased Degradation of Oxidative Phosphorylation Subunits.

21 Mediterranean Diet and Multi-Ingredient-Based Interventions for the Management of Non-Alcoholic Fatty Liver Disease

22 Nonalcoholic Fatty Liver Disease in South Asia.

23 Whole Grain Consumption and Its Effects on Hepatic Steatosis and Liver Enzymes in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial.

24 Leptin/adiponectin ratio correlates with hepatic steatosis but not arterial stiffness in nonalcoholic fatty liver disease in Japanese population

25 Intermediary effect of inflammation on the association between dietary patterns and non-alcoholic fatty liver disease.

26 Lifestyle Intervention Framework for Obese Patients with Non-alcoholic Fatty Liver Disease - a Tool for Health Professionals in Resource Constraint Settings.

27 Fat and sugar—a dangerous duet. A comparative review on metabolic remodeling in rodent models of nonalcoholic fatty liver disease

28 Endoscopic bariatric and metabolic therapies for non-alcoholic fatty liver disease

29 NLRP3 inhibitor glibenclamide attenuates high-fat diet and streptozotocin-induced non-alcoholic fatty liver disease in rat: studies on oxidative stress, inflammation, DNA damage and insulin signalling pathway.

30 Asporin levels are low in patients with nonalcoholic fatty liver disease and increase after vitamin E treatment.

31 A STUDY OF METABOLIC PARAMETERS IN NON DIABETIC PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE - IMPORTANCE OF DYSLIPIDEMIA.

32 New dual peroxisome proliferator activated receptor agonist - Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: Integrated analysis of the real world evidence

33 Copper modulates sex-specific fructose hepatoxicity in nonalcoholic fatty liver disease (NALFD) Wistar rat models.

34 Adipocytokine Regulation and Antiangiogenic Activity Underlie the Molecular Mechanisms of Therapeutic Effects of Phyllanthus niruri against Non-Alcoholic Fatty Liver Disease.

35 Investigating effect of Helicobacter pylori treatment on improvement of non-alcoholic fatty liver parameters: a randomized trial

36 Potential implications of COVID-19 in non-alcoholic fatty liver disease.

37 Effects of green tea or green tea catechin on liver enzymes in healthy individuals and people with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized clinical trials

38 The effect of green tea extract supplementation on liver enzymes in patients with nonalcoholic fatty liver disease

39 Treatment with a novel oleic-acid-dihydroxyamphetamine conjugation ameliorates non-alcoholic fatty liver disease in obese Zucker rats.

40 Psoralea corylifolia L. Seed Extract Attenuates Nonalcoholic Fatty Liver Disease in High-Fat Diet-Induced Obese Mice

41 THE THERAPEUTIC IMPACT OF PROBIOTICS ON NONALCOHOLIC FATTY LIVER DISEASE IN PEDIATRICS: A SYSTEMATIC REVIEW

42 obese children with metabolic syndrome have 3 times higher risk to have nonalcoholic fatty liver disease compared with those without metabolic syndrome

43 investigating the deregulation of metabolic tasks via minimum network enrichment analysis (minea) as applied to nonalcoholic fatty liver disease using mouse and human omics data.

44 bariatric surgery and nonalcoholic fatty liver disease: current and potential future treatments

45 ft3/ft4 ratio predicts non-alcoholic fatty liver disease independent of metabolic parameters in patients with euthyroidism and hypothyroidism

46 the state of pancreatobiliary system and intestinal microflora in children with nonalcoholic fatty liver disease

47 how useful are monogenic rodent models for the study of human non-alcoholic fatty liver disease?

48 mechanisms and implications of age-related changes in the liver: nonalcoholic fatty liver disease in the elderly

49 associação entre doença hepática gordurosa não alcoólica e marcadores de lesão/função hepática com componentes da síndrome metabólica em indivíduos obesos classe iii association between non-alcoholic fatty liver disease and liver function/injury markers with metabolic syndrome components in class iii obese individuals

50 misregulation of ppar functioning and its pathogenic consequences associated with nonalcoholic fatty liver disease in human obesity

51 resveratrol inhibits nonalcoholic fatty liver disease in rats

52 predictors of liver fat and stiffness in non-alcoholic fatty liver disease (nafld) – an 11-year prospective study

53 role of bariatric surgery in treatment of non-alcoholic fatty liver disease

54 the potential role of iron and copper in pediatric obesity and nonalcoholic fatty liver disease

55 the relationship between nonalcoholic fatty liver disease and colorectal cancer: the future challenges and outcomes of the metabolic syndrome

56 the effects of melatonin in patients with nonalcoholic fatty liver disease: a randomized controlled trial

57 diet-induced metabolic hamster model of nonalcoholic fatty liver disease

58 a review of western and traditional chinese medical approaches to managing nonalcoholic fatty liver disease

59 nonalcoholic fatty liver disease: a clinical approach and review

60 essential phospholipids in the treatment of nonalcoholic fatty liver disease

61 fbxw7 suppresses hmgb1-mediated innate immune signaling to attenuate hepatic inflammation and insulin resistance in a mouse model of nonalcoholic fatty liver disease

62 practical approaches to the nutritional management of nonalcoholic fatty liver disease

63 correlation of liver fat content with serum vitamin a level and insulin resistance in patients with nonalcoholic fatty liver disease

64 the dual role of nrf2 in nonalcoholic fatty liver disease: regulation of antioxidant defenses and hepatic lipid metabolism

65 lifestyle interventions for the treatment of non-alcoholic fatty liver disease

66 rimonabant improves oxidative/nitrosative stress in mice with nonalcoholic fatty liver disease

67 role of mitochondria in hiv infection and associated metabolic disorders: focus on nonalcoholic fatty liver disease and lipodystrophy syndrome

68 nonalcoholic fatty liver disease in patients investigated for elevated liver enzymes

69 genetic factors in the pathogenesis of nonalcoholic fatty liver and steatohepatitis

70 a noninvasive score model for prediction of nash in patients with chronic hepatitis b and nonalcoholic fatty liver disease

71 risk factors for non-alcoholic fatty liver disease: a multivariate analysis

72 safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic fatty liver disease

73 developmental programming of nonalcoholic fatty liver disease: the effect of early life nutrition on susceptibility and disease severity in later life

74 n-3 pufa status predicts non-alcoholic fatty liver disease (nafld) in older australians

75 mtp genetic variants associated with non-alcoholic fatty liver in metabolic syndrome patients

76 the gut microbiota, intestinal permeability, bacterial translocation, and nonalcoholic fatty liver disease: what comes first?

77 non-alcoholic fatty liver disease (nafld) in different populations: a clinical and epidemiological study – sample of são josé do rio preto

78 effect of alkaloids from nelumbinis plumula against insulin resistance of high-fat diet-induced nonalcoholic fatty liver disease in mice

79 influence of nutrient correction on adiponectin circulating level and cardiovascular risk factors in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease

80 peroxisome proliferator-activated receptor genetic polymorphisms and nonalcoholic fatty liver disease: any role in disease susceptibility?

81 pathology of nonalcoholic fatty liver disease (nafld) associated with obesity: pathogenetic mechanisms

82 development of a non-invasive model to improve the accuracy of determining liver fibrosis stage in nonalcoholic fatty liver disease

83 chronic kidney disease and nonalcoholic fatty liver disease—is there a link?

84 obesity and nonalcoholic fatty liver disease: metabolic risks and their correction

85 establishment and comparison of juvenile female mouse models of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

86 Endotoxin Producers Overgrowing in Human Gut Microbiota as the Causative Agents for Nonalcoholic Fatty Liver Disease

Keyword Connections

Journals

Research Groups

Bibliographies